相关实验视频

Updated: Jun 24, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

坐标蛋白质基因组分析确定了3q26AML中可药物治疗的PA2G4-MYC轴

Matteo Marchesini^1,2,3, Andrea Gherli^1,2, Elisa Simoncini^1,2

¹Department of Medicine and Surgery, University of Parma, Parma, Italy.

Nature communications

|June 4, 2024

概括

基斯脱乙酶抑制剂 (HDACis) 在急性髓性白血病 (AML) 中抑制EVI1基因. 向PA2G4蛋白质可以提高HDACi的疗效,为3q26AML提供新的治疗策略.

科学领域:

血液学血液学血液学
分子生物学分子生物学
癌症研究癌症研究

背景情况:

生态热带病毒整合位点-1 (EVI1/MECOM) 基因过度表达定义了一个具有3q26异常的急性髓性白血病 (AML) 的致命亚组.
基因组脱乙酶抑制剂 (HDACis) 显示出抑制EVI1的潜力,但它们在3q26AML中的精确机制需要阐明.

研究的目的:

通过剖析EVI1调节来研究3q26AML中的HDACis抗白血病机制.
确定与共转录复合体中与EVI1相互作用的关键蛋白质及其在HDACi反应中的作用.

主要方法:

高通量基于细胞和基因表达的查,以识别EVI1抑制剂.
在接受HDAC抑制剂治疗的患者中分析骨髓白血病细胞表达动态.
重建EVI1染色体相关的共转录复合体,重点关注与增殖相关的2G4 (PA2G4) 蛋白.

主要成果:

过度表达PA2G4使得AML细胞对HDACis产生抗性.
基因和小分子抑制PA2G4有效地废除了EVI1在3q26AML细胞和患者衍生的异种移植中的表达.
PA2G4在调解EVI1的白血病信号方面发挥着至关重要的作用.

结论:

在3q26AML中,PA2G4是EVI1瘤性途径的关键调解者.
针对PA2G4与HDACis结合,为3q26AML提供了一个有希望的治疗策略.
这项研究强调了PA2G4作为一种潜在的治疗点,用于开发针对这种侵袭性AML亚型的新疗法.

更多相关视频

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

相关概念视频

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...